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ABSTRACT
Short-term breastfeeding and early exposure to complex dietary pro-
teins, such as cow milk proteins and cereals, or to fruit, berries, and
roots have been implicated as risk factors for b cell autoimmunity,
clinical type 1 diabetes, or both. The Trial to Reduce Insulin-de-
pendent diabetes mellitus in the Genetically at Risk (TRIGR) is an
international, randomized, double-blind, controlled intervention tri-
al designed to answer the question of whether weaning to an exten-
sively hydrolyzed formula in infancy will decrease the risk of type 1
diabetes later in childhood. In our pilot study, weaning to a highly
hydrolyzed formula decreased by ’50% the cumulative incidence
of one or more diabetes-associated autoantibodies by a mean age of
4.7 y. This finding was confirmed in a recent follow-up analysis to
10 y of age. Currently, the full-scale TRIGR takes place in 77
centers in 15 countries. The TRIGR initially recruited 5606 new-
born infants with a family member affected by type 1 diabetes and
enrolled 2159 eligible subjects who carried a risk-conferring HLA
genotype. All recruited mothers were encouraged to breastfeed. The
intervention lasted for 6–8 mo with a minimum study formula ex-
posure time of 2 mo, and hydrolyzed casein and standard cow milk–
based weaning formulas were compared. Eighty percent of the par-
ticipants were exposed to the study formula. The overall retention
rate over the first 5 y was 87%, and protocol compliance was 94%.
The randomization code will be opened when the last recruited
child turns 10 y of age (ie, in 2017). Am J Clin Nutr 2011;94
(suppl):1814S–20S.
INTRODUCTION
Type 1 diabetes is characterized by the selective loss of insulin-
producing b cells in the pancreatic islets in genetically susceptible
individuals. The clinical disease presentation is preceded by an
asymptomatic period of highly variable duration (1). During that
period diabetes-associated autoantibodies appear in the peripheral
circulation as markers of emerging b cell autoimmunity. Evidence
suggests that b cell autoimmunity may be induced early in life
(2, 3). In parallel, recent studies have shown that the incidence
of type 1 diabetes is increasing even faster than before among
children in developed countries, among those ,5 y of age in
particular (4, 5). This scenario implies that any measure aimed at
primary prevention of type 1 diabetes (ie, prevention of the ini-
tiation of the diabetic disease process) has to start in infancy.
Early feeding may modify the risk of type 1 diabetes later in life.
Short-term breastfeeding and early exposure to complex dietary
proteins, such as cow milk proteins and cereals, or to fruit, berries,
and vegetable roots have been implicated as risk factors for
advanced b cell autoimmunity or clinical type 1 diabetes (6, 7).
Early nutritional intervention could offer a safe, preventive
modality for type 1 diabetes without the risks of aggressive
immune interventions and has, in fact, been successful in rele-
vant animal models of autoimmune diabetes, although the data
are not uniform (8–11).
TRIGR stands for Trial to Reduce Insulin-dependent diabetes
mellitus in the Genetically at Risk. It is an international, ran-
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domized, double-blind, controlled intervention trial designed to
answer the question of whether weaning to an extensively hy-
drolyzed formula in infancy will decrease the risk of type 1
diabetes later in childhood. This review focuses on the rationale,
design, accomplishments, and challenges of the trial, and possible
mechanisms to mediate the putative protective effect. In addition,
we present preliminary outcome data from the Finnish TRIGR
pilot.
EARLY FEEDING AS A RISK FACTOR FOR TYPE 1
DIABETES
We have recently reviewed the role of factors related to infant
nutrition in the development of b cell autoimmunity and type 1
diabetes, and the potential mechanistic pathways involved (12).
Early nutrition clearly represents one of the first environmental
determinants to which an infant is exposed. Given that the first
signs of b cell autoimmunity may emerge during the first year of
life in subjects who later progress to overt type 1 diabetes, it is
likely that in most cases the disease process is initiated early in
life. So far, no specific dietary factor or nutrient in infancy has
been unequivocally shown to be involved in the development of
type 1 diabetes. Evidence suggests, however, that dietary com-
ponents may be critical factors that predispose to or protect
against type 1 diabetes. In addition to short breastfeeding and
early exposure to complex foreign proteins or fruit, berries, and
root vegetables, lack of supplementation with vitamin D, heavy
birth weight, and rapid weight gain in infancy have been im-
plicated as risk candidates.
More research is definitely needed to confirm the contribution
of early dietary factors to the development of b cell autoim-
munity and clinical type 1 diabetes. The mechanistic pathways
have to be defined as well. It is important to identify early di-
etary elements involved in the disease process that results in
clinical type 1 diabetes, because the recognition of such deter-
minants may provide measures for safe and effective primary
prevention of type 1 diabetes aimed at inhibition of the initiation
of b cell autoimmunity.
RATIONALE FOR THE TRIGR
A group of international investigators reached a consensus in
the late 1990s that there is sufficient evidence that suggests
a deleterious effect of early weaning to complex diets for the
design of a primary prevention trial in children who carry genetic
susceptibility to type 1 diabetes. It is important to note that the
TRIGR does not, in fact, test the cow milk risk hypothesis, but
instead analyses the effect of an extensively hydrolyzed weaning
diet. Epidemiologic studies in this area have reached conflicting
conclusions, likely explained by insufficient power and inability
to address confounding factors such as the variations in feeding
practices and the varied prevalence of hydrolyzed formula use
and other foreign protein additives. Observational studies require
wide differences, and the brevity of exclusive breastfeeding in
most developed countries limits the power of such studies. Poor
associations can be expected in studies of a ubiquitous agent such
as cow milk, where exposure is nearly uniform. For example, the
causal link between wheat and celiac disease was only uncovered
through unplanned intervention (13): the wheat-deficient World
War II diet in The Netherlands and its postwar improvement
identified a culprit autoimmune disease–causing agent (ie, dietary
gluten). This substantiates the critical importance of controlled
intervention trials with sufficient power to arrive at conclusive
outcomes.
The principal hypothesis in the TRIGR is simple and has
proved testable: weaning to an extensively hydrolyzed formula
will decrease the likelihood of type 1 diabetes in genetically
susceptible children. If the hypothesis is proven correct, primary
prevention of a considerable number of affected cases, with
a decrease in the associated morbidity, mortality, and health care
costs, would for the first time become a realistic goal. An ad-
ditional benefit of the study is the provision of a platform, as well
as a large data and sample repository for mechanistic studies that
will shed new light on the progression of diabetic autoimmunity
from its early beginnings, and for collaborations with other trials
and studies in the field. If the intervention proves ineffective, this
would obviate the need for more expensive association studies
and remove the anxieties that surround weaning and infant feeding
in families with type 1 diabetes, which would avoid unnecessary
use of expensive hydrolysates. This would uncover a major,
unprecedented difference from the rodent models, where casein
hydrolysate has a uniformly preventive effect. Such a difference
between rodent and human diabetes would affect the way we
transfer insight from mouse to man.
The TRIGR effort constitutes the first-ever primary prevention
trial for type 1 diabetes. In contrast to secondary prevention strategies,
which attempt to arrest the progression of established islet au-
toimmunity and must identify prediabetes through screening, the
innocuous TRIGR strategy could be applied to the general
population with increased genetic risk, from which 83–98% of
new cases with type 1 diabetes are derived (14).
EXPERIENCES FROM THE TRIGR PILOT
One of the few intervention trials of infant nutrition performed
to date is the TRIGR pilot (15, 16). In this pilot, 230 Finnish
infants at increased risk of type 1 diabetes were randomly assigned
at weaning to either an extensively hydrolyzed formula or a
conventional cow milk–based formula before 8 mo of age. The
increased diabetes risk was based on a positive history of type 1
diabetes in a first-degree relative and, in addition, the participant
had to carry an HLA genotype that conferred enhanced disease
risk (14). During the intervention period the families were asked
not to give any food products that contained cow milk or bovine
serum albumin to their infants. The intervention resulted in a
postponement of the introduction of intact cow milk proteins by
several months in the active intervention group. After follow-up
to a mean age of 4.7 y, an interim analysis showed that the
nutritional intervention in infancy resulted in a decrease in most
signs of b cell autoimmunity in the range of 50–60%. After
adjustment for the observed difference in the exposure time to
the study formula there was a significant decrease in the cumu-
lative incidence of both islet cell antibodies and positivity for at
least one of the 4 autoantibody reactivities analyzed (15).
A recent follow-up analysis up to 10 y of age showed that this
early nutritional intervention significantly decreased the appear-
ance of one or more autoantibodies. The hazard ratio decreased
further after adjustment for the duration of study formula exposure.
Sixteen out of 230 participants (7%), 7 (6%) in the casein hy-
drolysate group and 9 (8%) in the control group, had progressed
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to overt type 1 diabetes. In an intention-to-treat analysis, the risk
of type 1 diabetes was not significantly associated with the
feeding intervention (casein hydrolysate compared with control;
hazard ratio: 0.80; 95% CI: 0.30, 2.14). However, 3 children who
progressed to overt type 1 diabetes dropped out before 3 mo of
age, 2 within 2–4 d after birth and the third just before the 3-mo
visit. All 3 children had been randomly assigned to the casein
hydrolysate group, but none had received any study formula.
Accordingly, the number of progressors per protocol (“treatment
received”) was 4 (4%) in the casein hydrolysate group and 9 (8%)
in the control group. The per protocol hazard ratio for type 1
diabetes was 0.40 (95% CI: 0.11, 1.51). The results from the
TRIGR pilot suggest that it may be possible to manipulate
spontaneous b cell autoimmunity by nutritional intervention
during infancy. Accordingly, early nutritional intervention as
applied in the TRIGR provides an attractive preventive strategy,
because it can be implemented relatively easily as a public health
measure.
DESIGN OF THE TRIGR
The full-scale TRIGR asks whether it is possible to decrease 1)
the frequency of disease-associated autoantibodies and/or clinical
diabetes by 6 y of age and 2) the cumulative incidence of diabetes
by 10 y of age by weaning to a highly hydrolyzed formula over the
first 6–8 mo of life. The study design has been described in detail
previously (17, 18). In brief, the TRIGR study population com-
prises newborn infants who have first-degree relatives affected by
type 1 diabetes (ie, a mother, father, or sibling) and who meet the
HLA inclusion but none of the exclusion criteria. Blood for HLA
genotyping was collected from cord blood and sent to the conti-
nental central laboratory within 8 d of birth, and results were sent
to the Data Management Unit within 2 wk of age for assessment
and confirmation of eligibility, which were then forwarded elec-
tronically to the centers. This international, double-blinded, pro-
spective, placebo-controlled intervention trial comprises 77 centers
in 15 countries on 3 continents. The enrollment began on 1 May
2002, and ended on 6 February 2007.
The sample size estimate was based on the following assump-
tions: 1) a confidence level of 95%, 2) a statistical power of 80%, 3)
a decrease of 40% in the hazard rate of type 1 diabetes in the in-
tervention group, 4) a dropout rate of 20%, and 5) a frequency of
10% of exclusive breastfeeding up to 6 mo of age. The spontaneous
cumulative incidence of type 1 diabetes by 10 y of age was esti-
mated to be 7.6% among children who fulfilled the inclusion
criteria of the trial (19). These assumptions resulted in a recruit-
ment target of 2032 eligible infants. As a consequence of successful
recruitment the enrollment target was exceeded by 6% to 2159
randomly assigned and eligible subjects.
The children were randomly assigned to the 2 treatment groups
in a 1:1 ratio with the use of randomly permuted blocks. Random
assignment was balanced within each center/country that par-
ticipated. Web-based randomization procedures proceeded effi-
ciently. The infants were assigned one of the 4 color-coded,
blinded formulas, 2 of which contained the hydrolyzed test
formula, 2 the control formula. The randomization code is known
only to the manufacturer and the principal investigator of the Data
Management Unit, under supervision of the Data Safety and
Monitoring Board. The code will be opened when the youngest
participant turns 10 y.
HLA genotyping
Cord blood was obtained whenever possible and, if un-
obtainable, a heel stick blood sample was collected on filter paper
and sent immediately to the Turku (Europe and Australia) or
Pittsburgh (North America) laboratories for HLA genotyping.
HLA genotyping for the selected DQB1 and DQA1 alleles was
performed with the use of sequence-specific oligonucleotide
hybridization, and quality control was maintained between the
2 laboratories. The following genotypes were regarded as eli-
gible: 1) HLA-DQB1*02/ DQB1*0302; 2) HLA-DQB1*0302/x
(x 6¼ DQB1*02, DQB1*0301, or DQB1*0602); 3) HLA-
DQA1*05-DQB1*02/y (y 6¼ DQA1*0201-DQB1*02, DQB1*0301,
DQB1*0602, or DQB1*0603); and 4) HLA-DQA1*03-DQB1*02/z
(z 6¼ DQA1*0201-DQB1*02, DQB1*0301, DQB1*0602, or
DQB1*0603).
Intervention
Whenever supplementary milk feeding was needed during the
intervention period, subjects received either the test formula
based on extensively hydrolyzed casein (Nutramigen; Mead
Johnson Nutrition, Evansville, IN) or a control formula created
by the company for this study made with intact (80%) and hy-
drolyzed (20%) milk protein to mask the taste and smell dif-
ferences between the 2 formulas. All recruited mothers were
encouraged to breastfeed their infants.
Follow-up during and after intervention
Clinical assessment, interviews, and blood sampling were
performed at the ages of 3, 6, 9, 12, 18, and 24 mo and continue
annually until 10 y of age or until manifestation of type 1 di-
abetes. Clinical data at each visit (eg, weight, height, adverse
events, infections, and so forth) are recorded and transmitted
electronically to the Data Management Unit. Cow milk anti-
bodies [immunoglobulin (Ig) G and IgA] (20) and a-casein
antibodies (IgG and IgA) (21) were measured within 2 mo of
sampling up to the 9-mo visit, to be used as efficacy and com-
pliance markers of the intervention, whereas other laboratory
tests are scheduled in batches. Diabetes-predictive autoanti-
bodies (islet cell antibodies, insulin autoantibodies, and anti-
bodies to the 65-kDa isoform of glutamic acid decarboxylase
and the protein tyrosine phosphatase-related IA-2A protein) are
analyzed from the autoantibody specimens obtained at each
study center visit. A heparin blood sample is also obtained at
each sampling time. These samples are sent fresh to the core
laboratories in Helsinki and Toronto for isolation of mono-
nuclear cells for mechanistic studies of T cell responses. Local
measurements of random plasma glucose and glycosylated he-
moglobin are performed at each visit from 12 mo onwards and
are reported to the Data Management Unit. The specimen for
plasma glucose is preferentially obtained 1–2 h postprandially.
In the presence of hyperglycemia or elevated glycosylated he-
moglobin, an oral-glucose-tolerance test (OGTT) is recom-
mended to exclude or confirm the diagnosis of diabetes. An
OGTT is performed in all nondiabetic subjects at 6 and 10 y of
age. If the first OGTT is diabetic according to World Health
Organization criteria, a second confirmatory test is required to
verify the diagnosis.
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WHY SHOULD AN EXTENSIVELY HYDROLYZED
FORMULA PROTECT AGAINST b CELL
AUTOIMMUNITY AND TYPE 1 DIABETES?
The mechanism or mechanisms through which a highly hy-
drolyzed formula may provide protection against b cell auto-
immunity and type 1 diabetes are not delineated. One may
speculate about potential mechanisms, such as 1) elimination of
early exposure to intact bovine insulin, 2) decreased gut per-
meability, 3) induction of the maturation of regulatory T cells in
the gut-associated lymphoid tissue, and/or 4) modification of the
gut microflora (Figure 1).
The casein-based formula used as the intervention modality in
this study is highly hydrolyzed and does not contain intact
proteins. Less than 0.3% of the peptides have a molecular weight
.2000 Da. Accordingly, the formula is free of intact bovine
insulin, which is present in cow milk (22). Vaarala et al (23)
showed that infants who were fed a conventional cow milk–
based formula before 3 mo of age developed an immune re-
sponse to bovine insulin that differs from human insulin by 3
amino acids. Normally, these infants developed oral tolerance to
bovine insulin over time, reflected by the decline in immune
responses to insulin. Interestingly, those infants who presented
with early signs of b cell autoimmunity lacked the capacity to
mount oral tolerance to bovine insulin. In such individuals the
immune response induced by bovine insulin might at some point
be diverted to target self-insulin and insulin-producing b cells,
and thereby contribute to the disease process that results in type
1 diabetes. Weaning to a highly hydrolyzed formula will post-
pone the exposure to intact bovine insulin and allow for matu-
ration of the mechanisms that control oral tolerance.
Some evidence suggests that children who present with type 1
diabetes have increased gut permeability. Such children have been
reported to have elevated concentrations of antibodies and higher
levels of T cell responses to certain dietary antigens (20, 24–28).
Recent observations based on the TRIGR pilot have shown that
those children who later progressed to clinical type 1 diabetes
already had elevated antibody concentrations to cow milk proteins
in infancy (29). This may imply that children who present with
type 1 diabetes have increased gut permeability early in life. On the
other hand, elevated concentrations of such antibodies may reflect
dysregulation of the gut-associated immune system, which is the
most extensive immune organ in the body.
In addition to increased gut permeability, subclinical intestinal
inflammation has been reported in children with type 1 diabetes.
Intestinal biopsies from such children without concomitant celiac
disease have shown signs of intestinal immune activation (30, 31).
Special interest has been focused on regulatory T cells, which are
perceived to be crucially involved in the regulation of autoim-
munity. Intestinal biopsy studies showed a lack of intestinal acti-
vation of regulatory T cells in patients with type 1 diabetes, which
might explain the subclinical intestinal immune activation and
altered responses to dietary antigens seen in subjects with type 1
diabetes (32). No data are available on the effect of highly hy-
drolyzed formulas on the maturation of regulatory T cells in infants.
The microbial colonization of the gut experiences 2 critical
phases in the infant period, the first soon after birth and the other in
the weaning period. A Dutch study showed that the most important
determinants of the gut microbiota composition in infants were the
mode of delivery, type of infant feeding, gestational age, infant
hospitalization, and antimicrobial use (33). A comparison of the
intestinal microflora of breastfed and formula-fed infants showed
that bifidobacteria become dominant in all breastfed infants after
the initial colonization, whereas most formula-fed infants had
similar amounts of Bacteroides and bifidobacteria (34). Fecal
samples from breastfed infants comprised lactobacilli and
streptococci, whereas samples from formula-fed infants often
contained staphylococci, Escherichia coli, and clostridia. These
data show that infant feeding has an indisputable effect on the
intestinal microbiota. A very recent study indicates that the level
of bacterial diversity diminishes over time in children en route to
type 1 diabetes relative to that of matched nonautoimmune in-
dividuals (35). A striking finding of that analysis was the decline
in Firmicutes and increase in Bacteroidetes seen in the gut mi-
crobiome in the prediabetic period in those who progressed to
overt diabetes; the pattern was in conspicuous contrast to the
trend observed in healthy children in whom Firmicutes increased
as the Bacteroidetes declined. Another recent study confirmed
that Nutramigen prevents autoimmune diabetes in the disease-
prone biobreeding rat and has beneficial effects on intestinal
barrier integrity, regulatory cytokine production, and the micro-
flora composition in the gut (36).
It is intriguing that in a German intervention trial the same
extensively hydrolyzed formula as the one used in the TRIGR
decreased the risk of another immune-mediated disease (ie, al-
lergic dermatitis) during the first year of life in infants with
a positive parental history of atopy (37). A significant protective
effect could still be observed at 6 y of age, although the relative
risk had increased from 0.42 at 1 y of age to 0.80 (38). No
FIGURE 1. Possible mechanisms by which an extensively hydrolyzed
formula may protect against b cell autoimmunity and type 1 diabetes in
children at increased genetic disease risk. The highly hydrolyzed formula (1)
eliminates the exposure to intact bovine insulin (BI) present in conventional
cow milk–based formulas (2); may decrease intestinal permeability,
thereby decreasing the load of foreign peptides and proteins on the gut-
associated lymphoid tissue in lamina propria (3); may induce the
maturation of regulatory T cells (Treg) in the gut-associated lymphoid
tissue, the function of which suppresses other T cells and their cytokine
production, resulting in decreased intestinal inflammation; and/or (4) may
support “healthy” microbial (d) diversity in the gut. DC, dendritic cell;
HLA, human leukocyte antigen; IL, interleukin; INF-c, interferon c; T, T
cell; Th, T helper; TNF, tumor necrosis factor.
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protective effect could be observed in terms of asthma and al-
lergic rhinitis. Given that both autoimmune diseases, such as type
1 diabetes, and atopic diseases, such as allergic dermatitis, are
considered to reflect dysfunctional immune regulation, one is
tempted to suggest that the protective effect conferred by the
extensively hydrolyzed formula may be related to the function of
regulatory T cells. However, this is not the only possibility.
Feeding with the extensively hydrolyzed formula led to a tran-
sient lower weight gain during the first year of life in the German
trial (39). Increased weight gain in infancy has been reported
repeatedly to be a risk factor for type 1 diabetes later in childhood
(12) and, accordingly, a decreased weight gain in infancy could
be protective. However, we could not find any difference in linear
growth and weight gain over the first 5 y of life between those
randomly assigned to the extensively hydrolyzed formula and
those assigned to the conventional cowmilk–based formula in the
TRIGR pilot (15).
ACCOMPLISHMENTS OF THE TRIGR
Enrollment in the study cohort was completed in early 2007.
All the study planning parameters have been met or bettered: the
rate of exclusive breastfeeding is less than expected and subject
retention is better than expected. The additional 6% enrollment
provides a cushion against any greater than expected lost-to-
follow-up rate.Major study accomplishments are shown inTable 1.
All adverse events are reported electronically with the use of
on-line event-monitoring systems developed and supported by
the Data Management Unit. Serious events are also reported to
the local institutional review boards and the TRIGR International
Coordinating Center, and the Data Safety and Monitoring Board
Growth data are monitored routinely by the Data Safety Moni-
toring Board. No differences in growth variables (heights,
weights, and body mass indexes) by treatment arm have been
observed to date. All adverse events, which include those cate-
gorized as serious, are summarized by the TRIGR Data Man-
agement Unit and reviewed at each Data Safety and Monitoring
Board meeting. To date there have been no concerns regarding
safety issues and the study intervention.
Compliance with study visits, completion of data forms, and
collection and submission of serum samples is also monitored
closely. Subject-lost-to-follow-up and protocol-noncompliance
rates are currently ’13.2% (an estimate of 20% was used in the
TRIGR planning parameters). The study planned on a 10% rate
of exclusive breastfeeding by 6 mo of age and the observed
cumulative rate was 3.6%. Compliance with forms submission
(and, by implication, study visits) was, by the end of May 2010,
97.6%, adjusted for subjects lost to follow-up. Similarly, com-
pliance with the collection and submission of required study
samples is 92.6%.
Another important measure of protocol compliance is the
extent to which study families comply with the study intervention
and avoid intake of cow milk–containing foods during the in-
tervention period. Self-reported dietary compliance rates have
been very high. In addition, the study protocol routinely screens
for cow milk antibodies and this has shown a high degree of
dietary compliance during the intervention period, which con-
firms the self-reported data.
CHALLENGES OF THE TRIGR
The primary challenge of the TRIGR study in its present phase
is how to keep the families in the study until the participant reaches
the age of 10 y. The Study Group has recently decided to extend the
follow-up of all participants until the youngest child turns 10 y of
age. At that time the oldest participants will be 14 y old, and the
mean age of the participants will be’12 y. This further increases
the retention challenge. The arguments for the extended follow-up
are based on the considerations that the extension increases the
number of follow-up years by ’4000 y (an increase of 20%) and
provides information on whether the expected protective effect of
the intervention extends into puberty.
The dropouts in the TRIGR are classified into 2 categories. The
lost-to-follow-up subjects come from families who have not
attended 2 sequential follow-up visits and who cannot be located
and contacted. In addition, this category includes those families
who have refused any further contacts from the TRIGR. The
number of subjects lost to follow-up amounted to 35 (1.6%) at the
end of May 2010. The children who did not participate represent
families who have failed to attend 2 sequential study center visits
but with whom the study center remains in contact. The number
of such families was 249 (11.5%) by 31 May 2010. Over the last
year each study center has been asked to contact the families that
did not participate and invite them to rejoin and come to the next
TABLE 1
Major accomplishments and milestones in the full-scale Trial to Reduce Insulin-dependent diabetes mellitus in the
Genetically at Risk (TRIGR)
Milestone Current level (31 May 2010)
Design, translation, and distribution of the Manual of
Operations, forms and questionnaires; Web-based in 12
languages
Achieved in 6 mo
Identification and consent of 4936 pregnant mothers with at
least one family member with type 1 diabetes
5156 registered mothers (105% of the target)
2032 (45% of screened) HLA eligible infants enter
intervention study
2160 (106% of the target) eligible infants entered the trial,
which allowed for a 45% eligibility rate
Forms and visit compliance .80% 97.6%
Blood sample compliance .70% 92.6%
Lost to follow-up and not participating ,20% 13.2%
Exclusive breastfeeding .6 mo 10% 3.6%
Exposed to study formula ’80%
Blood sample repository (n = 200,000/10 y) ’145,000 collected to date (94% of scheduled samples)
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follow-up visit. This retrieval activity has resulted in an in-
creasing number of families who have rejoined the study.
One issue that has been discussed by the Study Group is the
scenario that will arise if an autoantibody-positive TRIGR par-
ticipant is invited to a trial aimed at secondary prevention of type
1 diabetes. The results of the autoantibody screening are released
to the families for the first time after the 6-y follow-up visit, and
subsequently the results are provided after each annual visit.
Accordingly, children with signs of b-cell autoimmunity are
identified. The TRIGR Study Group has decided that the auto-
antibody-positive TRIGR participants may take part in second-
ary prevention trials, provided they fulfill the inclusion criteria.
This decision is based on ethical considerations, because from
a scientific point of view an effective secondary prevention
should decrease the number of endpoints in the TRIGR and
thereby introduce a bias. Most secondary prevention trials have
so far excluded subjects who have or are involved in other in-
tervention trials. If an effective secondary prevention strategy
for type 1 diabetes emerges before the end of the TRIGR, the
participants and their families will be informed and encouraged
to engage in such a treatment.
FUTURE SCENARIOS
Asmentioned earlier, the TRIGR study has 2 endpoints. The first
endpoint (ie, positivity of 2 diabetes-associated autoantibodies
and/or clinical diabetes by 6 y of age) will be reached in early
2013, when the youngest participant turns 6. The second and final
endpoint (ie, clinical diabetes by 10 y of age) will be reached in
early 2017. The issue has been raised as to whether the follow-up
of the trial participants should continue if there is a highly sig-
nificant difference or no difference whatsoever in the 6-y endpoint.
The Study Group feels strongly that the follow-up should continue
in any case up to early 2017, when the youngest participant turns
10 y, to assess the final outcome of the trial. At this point one
cannot exclude the possibility that the intervention may modify the
natural history of b cell autoimmunity in any direction without
necessarily affecting progression to clinical disease.
There are 2 possible scenarios in terms of the outcome of the
TRIGR. If the intervention significantly decreases the rate of type
1 diabetes by 10 y of age, this would imply that infants at in-
creased risk of type 1 diabetes should be weaned to a highly
hydrolyzed formula. If the intervention does not have an effect,
this would lead to a recommendation that weaning to a highly
hydrolyzed formula does not decrease the risk of type 1 diabetes
and, accordingly, such formulas do not provide any benefits to
infants who carry increased genetic susceptibility to the disease.
The TRIGR study is powered to provide a definite answer to
the controversial question of whether weaning to a hydrolyzed
formula protects against initiation and progression of type 1
diabetes. This effort is the first-ever primary prevention trial for
type 1 diabetes. If the main hypothesis of the study is proven
correct, primary prevention of at least some cases of type 1
diabetes will become a realistic goal.
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